Source: Recombinant human produced in E. coli
Purity: > 90% by SDS-PAGE, apparent Mr ~ 28-kDa
Supplied: 1 μg in 50 μl of 50 mM Tris-HCl pH 7.0 buffer containing 14 mM β-mercaptoethanol, 1 mM benzamidine, 0.1 mM phenylmethanesulfonyl fluoride, 1 mM EDTA and 10% glycerol. Maintain in aliquots at -70° C. Avoid repeated thawing.
Synonyms: Eukaryotic Protein Synthesis Initiation Factor 4E Phosphorylation Site Mutant (Serine 209 to Alanine); eIF-4ES209A.
Background: Protein synthesis initiation factor 4E (eIF4E) is a mRNA Cap-binding protein involved in an early rate limiting step in the initiation of protein synthesis. eIF4E undergoes phosphorylation at Ser209 in response to growth factors and other extracellular stimuli. This reaction is thought to be catalyzed in cells by the mitogen-activated protein (MAP) kinase interacting kinases (Mnk's) and an insulin-stimulated cytosolic protamine kinase (cPK, GLO117-100) which is activated by members of the MAP kinase family. In addition, eIF4E undergoes phosphorylation at Thr210 following incubation with cPK. In cells, eIF4E occurs as a complex with inhibitory binding proteins (4EBP) and as part of the eIF4F complex which also contains eIF4A and eIF4G. In response to insulin and other extracellular stimuli, eIF4E is activated and recruited to the eIF4F complex following its dissociation from the inhibitory 4EBP. Over-expression of eIF4E leads to cell transformation and tumorigenesis.
Product Datasheet (pdf)
References: J Biol Chem 270, 14824-14828 ♦ J Biol Chem 270, 14597-14603 ♦ Biochime 76, 822-830 ♦ J Biol Chem 271, 11831-11837 ♦ J Biol Chem 270, 21684-21688
Related Products: eIF4E (5 μg) ♦ eIF4E (15 μg) ♦ eIF4E (30 μg) ♦ eIF4E(S209A) (5 μg) ♦ eIF4E(S209A) (15 μg) ♦ eIF4E(S209A) (30 μg) ♦ eIF4E(T210A) (5 μg) ♦ eIF4E(T210A) (15 μg) ♦ eIF4E(T210A) (30 μg) ♦ eIF4E(S209T210A) (5 μg) ♦ eIF4E(S209T210A) (15 μg) ♦ eIF4E(S209T210A) (30 μg) ♦ eIF4E(S53A) (5 μg) ♦ eIF4E(S53A) (15 μg) ♦ eIF4E(S53A) (30 μg) ♦ eIF4E(S124A) (5 μg) ♦ eIF4E(S124A) (15 μg) ♦ eIF4E(S124A) (30 μg) ♦ cPK